(Q50636145)

17 March 2018

title

A cost-of-illness study of Lyme disease in the United States. (English)

1 reference

17 March 2018

main subject

Lyme disease

0 references

United States of America

0 references

author name string

Maes E

series ordinal

1

1 reference

17 March 2018

Lecomte P

series ordinal

2

1 reference

17 March 2018

Ray N

series ordinal

3

1 reference

17 March 2018

publication date

1 September 1998

1 reference

17 March 2018

published in

Clinical Therapeutics

1 reference

17 March 2018

volume

20

1 reference

17 March 2018

page(s)

993-1008; discussion 992

1 reference

17 March 2018

issue

5

1 reference

17 March 2018

Anxiety and persistence of Lyme disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Global judgments versus decision-model-facilitated judgments: are experts internally consistent?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Prevention of Lyme disease after tick bites. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Western blotting in the serodiagnosis of Lyme disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

The overdiagnosis of Lyme disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Discounting in cost-effectiveness analysis of healthcare programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

Utilization and cost of serologic tests for Lyme disease in Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980081-7

7 January 2021

10.1016/S0149-2918(98)80081-7

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

9829450

1 reference

17 March 2018